Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SUMMER INFAN | SUMR | 9.94% |
| SCIENTIFIC L | SCIL | 8.00% |
| NEW ORIENTAL | EDU | 5.80% |
| FEDERAL MOGU | FDML | 5.80% |
| NATUS MEDICA | BABY | 5.69% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
SABESP keeps up its position as one of the largest water and sewage services providers in the world. It recorded a rise in billed water and sewage volume during the second quarter 2012, primarily due to a higher number of connections and acceleration in consumption. Its non-cyclical regulated utility business in the Brazilian emerging market is an attractive and relatively low-risk investment opportunity.
Despite a little setback emanating from a rise in cost of sales and services, long-term growth prospects compelled us to maintain an Outperform recommendation on the stock. Our $105.00 price objective results from 13.4x earnings multiple (2012).
Read the full Analyst Report on SBS